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Spell Checking Nature: Versatility of CRISPR/Cas9
for Developing Treatments for Inherited Disorders
Daria Wojtal,1,2,10 Dwi U. Kemaladewi,1,10 Zeenat Malam,1 Sarah Abdullah,1 Tatianna W.Y. Wong,1
Elzbieta Hyatt,1 Zahra Baghestani,1 Sergio Pereira,1,3 James Stavropoulos,4 Vincent Mouly,5
Kamel Mamchaoui,5 Francesco Muntoni,6 Thomas Voit,7 Hernan D. Gonorazky,1,4
James J. Dowling,1,2,4,8 Michael D. Wilson,1,2 Roberto Mendoza-Londono,4,8 Evgueni A. Ivakine,1,11
and Ronald D. Cohn1,2,4,8,9,11,*
Clustered regularly interspaced short palindromic repeat (CRISPR) has arisen as a frontrunner for efficient genome engineering. How-
ever, the potentially broad therapeutic implications are largely unexplored. Here, to investigate the therapeutic potential of CRISPR/
Cas9 in a diverse set of genetic disorders, we establish a pipeline that uses readily obtainable cells from affected individuals. We show
that an adapted version of CRISPR/Cas9 increases the amount of utrophin, a known disease modifier in Duchenne muscular dystrophy
(DMD). Furthermore, we demonstrate preferential elimination of the dominant-negative FGFR3 c.1138G>A allele in fibroblasts of an
individual affected by achondroplasia. Using a previously undescribed approach involving single guide RNA, we successfully removed
large genome rearrangement in primary cells of an individual with an X chromosome duplication includingMECP2. Moreover, removal
of a duplication of DMD exons 18–30 in myotubes of an individual affected by DMD produced full-length dystrophin. Our findings
establish the far-reaching therapeutic utility of CRISPR/Cas9, which can be tailored to target numerous inherited disorders.Introduction
Many bacteria and archaea use clustered regularly inter-
spaced short palindromic repeat (CRISPR)-Cas systems,
which are adaptive immune systems, to fight off foreign
DNA in the form of bacterial phages and/or plasmids.1 Spe-
cifically, the type II CRISPR/Cas system works through
RNA-directed endonuclease cleavage of the invading
genomic sequence. The invading sequence is captured
and inserted directly into the genome of the host organism
between CRISPR regions.2–4 After transcription and pro-
cessing of these loci, RNA-guided endonucleases are
made with the capability to target foreign nucleic acids
on the basis of complementarity with the RNA.5
Since the realization of the potential power of a pro-
grammable nuclease in editing mammalian genomes, the
CRISPR/Cas9 system has been developed as a technology
for multiple biological contexts.6,7 Regardless of the plat-
form, this system requires a mammalian-optimized Cas9
and a chimeric single guide RNA (sgRNA), which is made
up of CRISPR RNAs (crRNAs) and a trans-activating CRISPR
RNA (tracrRNA).6–9 The guide sequences are generally
17–20 bp long.10 Target sequences must be adjacent to a
protospacer-adjacent motif (PAM) for Streptococcus pyogenes
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between an RNA guide and its DNA target.3,4 Once present
in cells, Cas9 and the sgRNA form a complex, bind to the
target sequence, and make a double-stranded break (DSB)
in the target. The break is repaired via the cellular process
of non-homologous end joining (NHEJ), an error-prone
process that introduces insertions and deletions (indels)
into the target sequence. Targeted mutations can also be
introduced by co-transfection of single- or double-stranded
DNA templates to promote homology-directed repair
(HDR). To date, SpCas9 has been used broadly for achieving
efficient genome editing in a variety of species and cell
types, including human cell lines, bacteria, zebrafish,
yeast, mouse, fruit fly, roundworm, rat, common crops,
pig, and monkey (reviewed in Hsu et al.12).
Another application of the CRISPR/Cas9 tool is to regu-
late gene expression. This approach uses a catalytically
inactive or ‘‘dead’’ Cas9 (dCas9), which when bound to
DNA elements can repress transcription by sterically hin-
dering the RNA polymerase machinery,13 most likely by
stalling transcriptional elongation. Alternative strategies,
such as converting Cas9 into a synthetic transcriptional
activator by fusing it to multiple copies of VP16 acti-
vator,14–16 have been developed. Studies from several
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to a particular endogenous gene promoter leads to only
modest transcriptional upregulation.15–17 Furthermore,
the domains used in CRISPR/Cas9-based activation, such
as the VP16 decamer,18 act as recruiters for multiple com-
ponents of the pre-initiation complex19 and most impor-
tantly do not enzymatically affect the epigenetic form of
the chromatin.20 Instead, targeting a promoter with multi-
ple sgRNAsmight be a better alternative for increasing acti-
vation due to synergistic effects.15–17 Taken together, the
CRISPR/Cas9 genome-engineering system has provided
opportunities that have already revolutionized science in
all areas of biomedical research.
Although CRISPR/Cas9 has been widely used as a
research tool, its potential in far-reaching therapeutic ap-
plications has largely been unexplored. Most genetic disor-
ders are associated with a life-threatening or a life-limiting
disease trajectory, for which current clinical management
is mainly supportive in nature. Recently, CRISPR/Cas9
has been employed for loss-of-function mutations in
homozygous autosomal-recessive disorders (e.g., cystic
fibrosis and sickle-cell disease)21,22 and X-linked recessive
disorders (e.g., Duchenne muscular dystrophy [DMD
(MIM: 310200)])23–25 to correct the causative mutation
and/or restore the open reading frame. In order to
further explore the versatile and potentially broad thera-
peutic applications of the CRISPR/Cas9 technology, we
developed a pipeline in which genome-engineering strate-
gies use widely accessible cells from individuals affected
by various genetic conditions. We show that this system
can be employed for developing treatment strategies
that modulate expression of genes that are known
to play a critical role in disease pathogenesis. Further-
more, we demonstrate that CRISPR/Cas9 can be utilized
to therapeutically target autosomal-dominant, heterozy-
gous, gain-of-function mutations and large chromosomal
rearrangements.Material and Methods
Mapping the Duplication Junction
A series of probes near the junction were designed, and qPCR
followed by sequencing was used for mapping out the exact break-
point of the duplication. Primers for the MECP2 duplication were
50-CCCACAGAGTAGAGTGGAGCAG-30 (forward) and 50-TTAGA
CAGAGTCTCACTCCATCACC-30 (reverse). Primers for the dupli-
cation of DMD (MIM: 300377) exons 18–30 were 50-CAGCATCAT
GACCTGTTTCAATC-30 (forward) and 50-TTGTTAGAGGGCAGCA
AGTTTGT-30 (reverse).Cell Culture
Primary fibroblasts from individuals with achondroplasia (MIM:
100800), methyl-CpG binding protein 2 (MECP2 [MIM:
300005]) duplication syndrome (MIM: 300260), and DMD
involving a duplication of DMD exons 18–30 were obtained
from skin tags and established at the Hospital for Sick Children.
They were maintained in high-glucose DMEM supplemented
with 10% fetal bovine serum (FBS), L-glutamine, and 13 penicillinThe Amand streptomycin (all from Life Technologies). Immortalized DMD
myoblasts were obtained from the Institut de Myologie26 and
maintained in Skeletal Muscle Cell Growth Media (Promocell) at
37C with 5% CO2 incubation. The research ethic boards of
each institution approved all of the experiments.
sgRNA Design
All UTRN (MIM: 128240) guides were selected on the basis of their
proximity (50–500 bp) to the UTRN A or B transcription start site
(TSS) and subcloned into dCas9-VP160 (Addgene 48240).27 Each
plasmid contained a single locus-specific sgRNA in conjunction
with a catalytically inactive SpCas9. FGFR3 sgRNAs g1 and g2
were chosen on the basis of their proximity to the mutation in-
tended for editing and were subcloned into pSpCas9(BB)-2A-GFP
(Addgene 48138).28 Guides targeting the MECP2 duplication
were designed on the basis of the lowest possible off-target hits
within the genome,29 as well as their position within the duplica-
tion. The guides targeting the DMD duplication were designed on
the basis of the most active sgRNAs as computationally predicted
by the online Benchling Tool described by Doench et al.30 All
sgRNAs with a predicted activity score greater than 0.75 were
next analyzed by the CRISPR Design tool29 and ranked according
to the least possible number of potential off-target sites. The
best predicted sgRNAs (Table S1) were then subcloned into the
lentiCRISPR v.2 vector (Addgene 52961).31
Electroporation
For UTRN upregulation experiments, 3 mg of DNA composed of
combinations of sgRNAs cloned into a dCas9-VP160 plasmid
was electroporated into DMDmyoblasts. An equal amount of orig-
inal dCas9-VP160 plasmid served as a control. Electroporation was
conducted on 2 3 105 myoblasts per condition with the NEON
Transfection System (Life Technologies), which double pulsed cells
at 950 V and a pulse width of 30ms. Culturemediumwas replaced
the following day, and cells were harvested for protein analysis
4 days after electroporation.
Nucleoporation
53 105 achondroplasia fibroblasts were nucleoporated with a total
of 3 mg of DNAwith program U-023 on the Amaxa system and the
Primary Fibroblast Kit (Lonza). Cells were sorted by fluorescence-
activated cell sorting 4 days after nucleoporation, and DNA was
collected on the same day.
Lentivirus Production and Transduction
Production of lentiCRISPR and transduction into target cells were
performed as described by Sanjana et al.31 with a slight modifica-
tion. For production of the lentiCRISPR, 293T cells (ATCC) at 80%
confluency in a 10 cm petri dish were transfected with 10 mg of
transfer lentiCRISPR plasmid, 5 mg of the envelope (pCMV-
VSV-G, Addgene) plasmid, and 7.5 mg of packaging (psPAX2,
Addgene) plasmid via the calcium phosphate transfection
method. 60 hr after transfection, supernatant was collected,
centrifuged at 3,000 rpm for 10 min, and filtered through a
0.45 mm low-binding filter (Whatman).31 Fibroblasts affected by
MECP2 duplication syndrome were plated on a 24-well plate until
they were 60% confluent and then transduced with 1 ml lenti-
CRISPR plasmid containing MECP2 sgRNA A1 or A2. Each trans-
duction condition was performed in triplicate, and proliferation
medium was added to make the final volume 1.5 ml. Fibroblasts
with the DMD duplication were co-transduced with Ad-MyoDerican Journal of Human Genetics 98, 90–101, January 7, 2016 91
(Vector Biolabs) at 100 MOI in DMEM with 1% FBS (for inducing
their differentiation intomyoblasts) andwith a lentiCRISPR vector
containing DMD sgRNA 1, similarly to above. 3 days after trans-
duction, 2 mg/ml puromycin was added for selecting cells contain-
ing the lentiCRISPR-sgRNA constructs. DNA was collected 7 days
after puromycin selection, and proteins were collected 7 days after
differentiation.Western Blot
The cells were lysed with RIPA buffer (50 mM Tris HCl [pH 7.4],
150 nM NaCl, 1 mM EDTA, 1% deoxycholate, 1% NP40, and 1%
Triton X-100 supplemented with phosphatase and protease inhib-
itor cocktails [Roche]), and the protein concentration was
measured by bicinchoninic acid (BCA) assay. 25 mg of protein
lysates were resolved by western blot on 3%–8% Tris-acetate gels,
transferred to nitrocellulose membranes, and probed for utrophin
(MANCHO7 7E3, DSHB), dystrophin (MAB1692,Millipore), b-dys-
troglycan (MANDAG clone 7D11, DSHB), a-dystroglycan (kindly
provided by Kevin Campbell), and b-tubulin (SantaCruz).On-Target Editing Analysis
DNA transfected with Cas9 and FGFR3 sgRNA 1 or 2 was collected
with the DNA Blood and Tissue Extraction Kit (QIAGEN). At the
primary PCR step, DNA was amplified with primers FGFR3
50-GCCCTCTAGACTCACTGGCGTTACT-30 (forward) and FGFR3
50-TGCCCCAAAGTACCCTAGGCTCTACAT-30 (reverse) under the
following conditions: initial denaturation at 95C for 15 min, 15
cycles of denaturation at 95C for 30 s, annealing at 58C for
30 s, and extension at 72C for 30 s. Finally, there was a further
extension for 7 min at 72C before the samples were cooled and
stored at 4C. The secondary PCR was performed to incorporate
barcodes with the universal reverse primer 50-CCACTACGCC
TCCGCTTTCCTCTC TATGGGCAGTCGGTGATTCTGTTACCTGT
CGCTTGA-30 and either sgRNA 1 forward primer 50-CCATCTCAT
CCCTGCGTGTCTCCGACTCAGAAGAGGATTCGATTCTTTGCAG
CCGAGGAG-30 or sgRNA 2 forward primer 50-CCATCTCAT
CCCTGCGTGTCTCCGACTCAGCTAAGGTAACGATTCTTTGCAG
CCGAGGAG-30. The PCR conditions were 95C for 15 min, 15 cy-
cles of denaturation at 95C for 30 s, annealing at 60C for 30 s,
and extension at 72C for 30 s. Finally, there was a further exten-
sion for 7 min at 72C before the samples were cooled and stored
at 4C. A purified fusion amplicon library was submitted to the
sequencing facility at The Centre for Applied Genomics Facility
(TCAG) at The Hospital for Sick Children (Toronto) for quality
control, whereby the size of the amplicon library was checked
on a Bioanalyzer 2100 instrument (Agilent) and quantified by Qu-
bit (Invitrogen). Sequencing was performed at TCAG on an Ion
Torrent Proton with a PI chip V3. Each potential on-target site
was evaluated after corresponding sequencing reads were aligned
to the human reference genome (UCSC Genome Browser hg19).
The proportion of reads that matched the reference genome and
the proportion of those with insertions, deletions, and substitu-
tions near predicted cleavage sites were used for estimating the
on-target editing activity of a corresponding sgRNA. A custom Py-
thon script was written for assessing read support for evidence of
DNA editing given a BAM file, an anchor position P, and target
length L (8 nucleotides). All reads overlapping position P were ex-
tracted from the BAM file. Reads that did not extend at least 8 bp
beyond anchor point P were discarded. For each read, the 8 bases
extending past position P were extracted, and the overall fre-
quencies were calculated.92 The American Journal of Human Genetics 98, 90–101, January 7, 2Off-Target Analysis
Off-target analysis was conducted as follows for all lentivirus-deliv-
ery-based gene-editing experiments. Primers targeting loci corre-
sponding to each sgRNA’s top 20 off-target hits, as computed by
the CRISPR Design tool,29 were designed and used to amplify
DNA from each gene-editing experiment with custom GeneRead
DNaseq Targeted Panels (QIAGEN). ~200 bp amplicons were puri-
fied with magnetic beads, and library preparation was conducted
with sample-specific barcodes and the Ion Torrent Library Prepara-
tion Kit (Life Technologies) at TCAG at The Hospital for Sick Chil-
dren. Sequencing was performed with the Ion Torrent Proton.
Each potential off-target site was evaluated after corresponding
sequencing reads were aligned to the human reference genome
(hg19). A custom Python script was utilized similarly as described
above, and the proportion of reads that matched the reference
genome and the proportion of those with insertions, deletions,
and substitutions near predicted cleavage sites were used for esti-
mating the off-target activity of a corresponding sgRNA. The top
12 off-target hits computed by COSMID,32 which were not pre-
dicted by the CRISPRDesign tool,29 were assayedwith the GeneArt
Genomic Cleavage Detection Kit (Life Technologies) according to
the manufacture’s protocol.Results
Therapeutic Use of CRISPR/Cas9 for Modulating Gene
Expression
In order to explore the feasibility of utilizing a modified
version of CRISPR/Cas9 for therapeutic approaches based
on modulating gene expression, we aimed to upregulate
utrophin in skeletal-muscle cells of an individual with
DMD. DMD is an X-linked recessive neuromuscular disor-
der associated with muscle degeneration causing progres-
sive weakness. Pathogenic mutations in DMD lead to an
absence of the protein product, dystrophin, resulting in
a disruption of the dystrophin-glycoprotein complex
(DGC) at the sarcolemma. Increased amounts of utrophin
have previously been shown to compensate in part for the
loss of dystrophin.33 If successful, this approach would be
beneficial to all individuals affected by DMD, indepen-
dently of their primary genetic mutation. Here, we trans-
fected myoblasts of a DMD-affected individual (who
carries a deletion of DMD exons 45–52) with a catalytically
inactive SpCas9 fused to ten tandem repeats of a transcrip-
tional transactivator VP16 (dCas9-VP160)27 guided to
either the UTRN A or UTRN B promoter (Figure 1A).
Remarkably, we demonstrated that several sgRNAs target-
ing either promoter A34 or B35 upregulated utrophin
amounts such that they were 1.7- to 2.7-fold or 3.8- to
6.9-fold, respectively, higher than basal amounts (Figures
1B and 1C). Furthermore, we demonstrated that the com-
bination of guides targeting promoter B region, but not
A, further increased the amount of utrophin.
We then sought to investigate the transcriptional mech-
anisms that could explain the different potential of our A
and B guides to upregulate UTRN. We analyzed publicly
available data describing experimentally captured TSSs
(FANTOM536), high-resolution DNase I hypersensitivity016
Figure 1. Utilizing CRISPR/Cas9 to Modulate Expression of UTRN, a Disease-Modifying Gene in DMD Myoblasts
(A) Schematic diagram (not to scale) of sgRNAs targeting regions upstream of UTRN A (A1–A3) and B (B1–B4) TSSs.
(B) CRISPR/Cas9-mediated transcriptional activation of UTRN in DMD myoblasts. Amounts of utrophin, b-dystroglycan, and tubulin
were analyzed by western blot 4 days after transfection with dCas9-VP160 plasmid containing each sgRNA.
(C) The amount of utrophin was normalized to that of tubulin by densitometric analysis of four different experiments.
(D) Location of sgRNAs in relation to UTRN TSS, DNase I hypersensitivity footprints, and chromatin-state maps. sgRNAs are plotted
above experimentally determined TSSs obtained from a FANTOM5 assay of over 300 primary tissues. The maximum signal at each pro-
moter region is shown below the TSSs (CAGE tags). Digital DNase Footprinting (DGF) assays for fetal muscle and primary CD3 cells are
shown in blue (ENCODE). DGF assays for skeletal-muscle cells, skeletal muscle, and naive CD4 cells are shown in black. Chromatin-state
maps from the Roadmap Epigenomic Consortium are shown for skeletal-muscle cells (SkM), skeletal muscle (SM), and naive CD4 cells
(CD4N). Red indicates TSSs, and yellow indicates enhancer states. The A guides all fall within muscle promoter regions. The B guides fall
into an enhancer region immediately upstream of an annotated promoter region. In CD4 cells, this region is considered an active pro-
moter. At promoter B, the DGF footprint in muscle cells is weak in comparison to that in CD4 cells. Data were plotted according to po-
sitions from the UCSC Genome Browser. FANTOM5, DGF, and chromatin-state data were obtained from UCSC ‘‘Track Hubs.’’mapping (Digital Genomic Footprinting [DGF]37), and
chromatin states from the Roadmap Epigenomics Con-
sortium38 and ENCODE.39 We observed that in fetal and
adult skeletal muscle, there was a prominent DNase I foot-
print at the A promoter, but not at the B promoter
(Figure 1D; Figure S1), which is preferentially used in T
lymphocytes. These suggest that inmuscle cells, the poten-
tial to open chromatin and activate the B promoter is
greater than the potential at the already active A promoter.
Nevertheless, despitepossibledifferences in thepromoter
usage in muscle cells, even a modest ~1.7-fold increase in
the amount of utrophin (in comparison to basal amounts),
as observed with sgRNA A2, was accompanied by restored
amounts of b-dystroglycan, providing evidence for theThe Amfunctional relevance of this strategy. Our data demonstrate
that this adapted, sgRNA CRISPR/Cas9 approach is capable
of targeting expression levels of disease-modifying genes
that can be explored for various human disorders.
Allele-Specific Disruption of a Dominant-Negative,
Gain-of-Function Mutation
We next wanted to interrogate whether CRISPR/Cas9 can
be employed for achieving NHEJ-mediated allele-specific
disruption of a dominant-negative disease-causing allele.
We therefore assessed fibroblasts of an individual with
achondroplasia, which is the most common cause of
dwarfism in humans and is often associated with hydro-
cephalus, sleep apnea, and spinal stenosis. 98% of affectederican Journal of Human Genetics 98, 90–101, January 7, 2016 93
Figure 2. Targeted Elimination of
a Dominant-Negative, Gain-of-Function
Allele in the Receptor Gene FGFR3
(A) Position of FGFR3 sgRNA 1 in rela-
tion to that of the pathogenic FGFR3
c.1138G>A allele and theWT FGFR3 allele.
Lowercase letters denote the distinguishing
bases between the affected (a, red) and WT
(g, green) alleles.
(B) Quantification of major indels associ-
ated with alleles A and G in cells trans-
fected with Cas9 (white bars) or Cas9 and
sgRNA 1 (black bars).
(C) Positionof FGFR3 sgRNA2 in relation to
that of the pathogenic FGFR3 c.1138G>A
allele and the WT FGFR3 allele.
(D) Quantification of major indels associ-
ated with allele A and G in cells transfected
with Cas9 (white bars) or Cas9 and sgRNA
2 (black bars).individuals carry the same pathogenic dominant-negative,
gain-of-function mutation (c.1138G>A [p.Gly380Arg]) in
fibroblast growth factor receptor 3 (FGFR3 [MIM:
134934]). Given the sequence surrounding the region
of interest, we were able to design an allele-specific
FGFR3 sgRNA 1 complementary to the pathogenic allele
(Figure 2A). We then electroporated the achondroplasia fi-
broblasts with Cas9 and FGFR3 sgRNA 1 and used deep
sequencing to analyze the FGFR3 exon 9 region. We de-
tected a variety of indel types (Table S3), but 10.85% of
the total reads carried a 1 nt deletion on the pathogenic
allele (Figure 2B), consistent with its inactivation. Further-
more, the FGFR3 c.1138G>A mutation presents an un-
usual situation where the pathogenic SNP generates a
unique PAM sequence. The wild-type (WT) allele contains
a 50-GGG-30 PAM site, and the mutant FGFR3 c.1138G>A
allele has a 50-AGG-30 variant. The PAM is necessary for
Cas9 recognition of the target sequence, and the canonical
PAM for SpCas9 is 50-NGG-30,9 where any nucleotide can
constitute the first 50 position. Interestingly, recent ana-
lyses of activity of a vast library of sgRNAs detected a
PAM-specific bias,30 suggesting that unique differences
coupled with a precise sgRNA sequence might confer a
targeting discrimination. Hence, we utilized the 1 bp
discrepancy in the PAM-recognition sequence to design
PAM-discriminating sgRNA 2 (Figure 2C) in an attempt
to achieve allele-specific targeting in achondroplasia. Inter-
estingly, we found that the pathogenic A allele was tar-
geted more frequently than the G allele in that up to
9.8% of total reads carried a 2 nt deletion (Figure 2D; Table
S3). These data demonstrate that our designed sgRNA pref-
erentially targets the mutant allele. Altogether, we provide
evidence that both allele-specific and PAM-discriminating
sgRNAs can be used for preferential targeting of disease-
causing autosomal-dominant mutations.
Targeted Removal of a Large Duplicated
Chromosomal Rearrangement
With the development of powerful genome-analysis plat-
forms, there is growing evidence of the prevalence of94 The American Journal of Human Genetics 98, 90–101, January 7, 2copy-number variations (CNVs) associated with numerous
genetic conditions.40 However, to date no therapeutic
strategies have been developed to target these large
genomic rearrangements, such as that in MECP2 duplica-
tion syndrome. This is a rare condition associated with
intellectual disability and macrocephaly. It is caused by a
variably sized X chromosome CNV that includes a duplica-
tion of MECP2. In order to explore whether the CRISPR/
Cas9 technology could be utilized to target this CNV, we
first determined the exact orientation and breakpoint junc-
tion sequence of the duplication in a male individual with
this disorder to be a chrX: 153,420,649–153,142,419
(hg19) duplication with a CA insertion at the breakpoint
junction (Figure 3A). In this study, we explored an alterna-
tive therapeutic strategy of using the CRISPR/Cas9 system
in conjunction with only one sgRNA to remove a duplica-
tion (Figure 3B). The sgRNA will bind to two places within
a duplication, leading to the formation of two DSBs and
hence the removal of the intervening sequence, which
equates to the total size of the duplication. Duplication
removal could theoretically be achieved with two sgRNAs,
one of which targets the duplication junction (Figure 3B,
inset); however, it is dependent on the availability of
PAM-recognition sequences within this region. Further-
more, the one-sgRNA approach provides an opportunity
to evaluate the entire duplication sequence in order to
design RNA guides with the least possible off-targets,
thereby alleviating the sequence restrictions presented by
the two-guide approach. Moreover, using one instead of
two sgRNAs is therapeutically appealing given the limited
loading capacity of potential in vivo delivery vehicles such
as adeno-associated virus 9 (AAV9).
In the affected fibroblasts, the duplicated copy ofMECP2
couldbeprecisely removedwitha single sgRNAgiven its tan-
dem head-to-tail orientation. In order to test this hypothe-
sis, we designed two sgRNAs within the 278 kb duplication
while excluding any known coding regions or regulatory el-
ements (Figure 3A).We tested the activity of these guides in
primary fibroblasts of a healthy control individual by using
MECP2 sgRNAs A1 and A2with SpCas9, andwewere able to016
Figure 3. Targeted Removal of a 278 kb
X Chromosome Duplication Containing
MECP2
(A) Electropherogram of the X chromo-
some duplication junction; highlighted
in blue is the insertion of CA at the junc-
tion.
(B) Overview of the single-guide strategy for
removing the MECP2 duplication. The first
copy ofMECP2 is denoted by black and gray
bars, whereas the second copy is depicted
by dark and light-blue bars. The inset de-
scribes an alternate, less favorable duplica-
tion-removal strategy using two sgRNAs.
The relative positions of MECP2 sgRNAs
A1 and A2 are shown on the duplicated
region.
(C) Removal of the duplicated region was
detected with a PCR strategy using three
primers positioned to the duplicated locus.
P1 and P3 are universal to the region of in-
terest, whereas P2 only amplifies the dupli-
cation junction with P1.
(D) A Cas9 nuclease guided by sgRNA 1 or 2
or a GFP control was delivered to affected
fibroblasts via lentiviral particles. Three-
primer PCR demonstrated an accumulation
of the bottom band (corresponding to the
WT single-copy amplicon) and a decrease in the top band (corresponding to the duplicated copy).
(E) Densitometric analysis depicting a decrease in the ratio between the duplicated band and the WT band. **p < 0.01 (Student’s t test
from three independent experiments).showthat thedeletionprocessof a114kb fragmentoccurred
through precise end joining of the two ends upon the two
staggered Cas9-mediated DSBs (Figures S2B–S2D). Next, we
transduced primary dermal fibroblasts from a male with
MECP2 duplication syndrome with lentiCRISPR containing
eitherMECP2 sgRNAA1orA2.We isolatedDNA10daysafter
infection and employed a three-primer PCR detection strat-
egywhere primers 1 and3 (P1þ P3)were universal to the re-
gion of interest and amplified theWT, single-copy junction
and primer 2 (P2) was specific to the junction of the dupli-
cated region (Figure 3C). We were able to detect a loss of
the amplicon specific to the duplicated region and an accu-
mulation of the amplicon corresponding to a single WT
copy, demonstrating that theentire duplicationwas success-
fully removed after treatment (p< 0.01; Figures 3D and 3E).
Our results establish that a single-sgRNA approach provides
a highly efficient therapeutic strategy for removing chromo-
somal duplications and that this strategy canbe explored for
a number of different disorders caused by CNVs.
Given our successful removal of a large chromosomal
duplication, we next investigated whether a similar, sin-
gle-sgRNA approach could be applied to large exonic
duplications in DMD. Treatment strategies that target du-
plications in DMD have not been extensively studied to
date even though duplications of one or more exons
compose approximately 10% of the DMD mutation spec-
trum.41 We first determined the junction of a duplication
of exons 18–30 in a DMD-affected individual to be a
chrX: 32,552,206–32,413,149 (hg19) tandem duplication
with an AAAT insertion at the breakpoint junction
(Figure 4A). We co-transduced the affected fibroblastsThe Amwith adeno-MyoD to induce transdifferentiation of fibro-
blasts into myoblasts and lentiviral-vector-containing
DMD sgRNA 1. To assess for evidence of duplication
removal on a molecular level, we employed a three-primer
PCR strategy as previously described and illustrated in
Figure 4C. In the WT control, we detected a higher band,
corresponding to the amplification product of P1 þ P3,
whereas the duplication control showed two bands corre-
sponding to the P1þ P3 product and the duplication-junc-
tion-specific amplification product of P1 þ P2 at a ratio of
1:1. After lentiCRISPR treatment with sgRNA 1, but not
with LentiGFP, the ratio became skewed toward the top
band (p < 0.05; Figure 4D), indicating a conversion of
the duplicated allele toward the WT single copy. We next
explored whether the molecular transition toward the
WT allele leads to functional restoration of protein.
Remarkably, we detected full-length dystrophin (4.42%)
in transdifferentiated myotubes treated with the single
DMD sgRNA 1, and this was accompanied by restoration
of a-dystroglycan, a critical component of the DGC
(Figure 4E). All together, our data demonstrate that
CRISPR/Cas9-mediated removal of duplications results in
production of full-length functional dystrophin in myo-
tubes, which opens up entirely new treatment strategies
for individuals affected by DMD duplications.Discussion
Recent development of genome-editing technologies
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Figure 4. Genome-Editing Strategies for
Individuals with Duplication of DMD Exons
18–30
(A) Electropherogram of the junction of the
duplication of DMD exons 18–30; high-
lighted in blue is the insertion of AAAT at
the junction.
(B) Schematic of the position of DMD sgRNA
1 and the duplication-removal strategy.
(C) Schematic of the three-primer duplica-
tion-removal strategy.
(D) Targeted deletion of a 139 kb duplication
in DMD. PCR was performed on DNA from
three replicate experiments in which affected
myoblasts were transduced with LentiGFP
or lentiCRISPR Cas9 nuclease with DMD
sgRNA 1. The top band was amplified with
universal primers (P1 þ P3) to both an allele
with the duplication and a control. The bot-
tom band is specific to alleles harboring the
duplication (P1 þ P2). A decrease in the bot-
tom band, indicating removal of the dupli-
cated region, was only observed when Cas9
and sgRNA 1 were present.
(E) Western blot with antibodies against dys-
trophin, a-dystroglycan, and tubulin as a
loading control. The amount of dystro-
phin was normalized to that of tubulin by
densitometric analysis. *p < 0.05, **p <
0.01 (Student’s t test from three independent
experiments).Cas9 has generated enormous excitement across many
fields, including biological research, biotechnology, and
clinical medicine. Despite being a nascent technology,
Cas9 has been successfully used for generating an
increasing number of cellular and animal models for a
variety of basic research, and it has also been applied in
biotechnology. Furthermore, the CRISPR/Cas9 system
can be exploited for the development of genome-engineer-
ing therapies, which carries the potential to revolutionize
medical management in the future. Our current study de-
fines a pipeline in which genome-engineering strategies
use easily accessible cells from affected individuals and
provides evidence of the versatility of the CRISPR/Cas9
system, which can be employed for various genetic
conditions.
One of the opportunities to therapeutically utilize the
CRISPR/Cas9 technology is to affect disease phenotype
and progression by modulating expression of genes that
are known to play a critical role in disease pathogenesis.
An example of a gene that ameliorates the progression of
disease is UTRN, which has been known to partly compen-
sate for the loss of dystrophin in DMD (reviewed in96 The American Journal of Human Genetics 98, 90–101, January 7, 2016Fairclough et al.42). DMD is a life-
limiting, progressive neuromuscular
disorder, and currently the only thera-
pies available are corticosteroids, which
slightly improve the phenotype of indi-
viduals affected by DMD and are associ-
ated with a number of significant sideeffects (reviewed in Bushby et al.43). Utrophin’s ability to
modify disease progression has been established in multi-
ple experiments using the dystrophin-negative mdx
mouse, and it is suggested that increasing levels of UTRN
mRNA over 2-fold more than basal levels is sufficient to
have functional benefit.42,44 In addition, small molecules
that target upregulation of utrophin are currently in early
stages of clinical trials.33 Here, we provide an alternative,
CRISPR/Cas9-mediated therapeutic approach for upregu-
lating utrophin and using sgRNAs to target two UTRN pro-
moters. Our approach upregulated the amount of utrophin
such that it was 1.7- to 6.9-fold more than the basal
amount and restored the amount of b-dystroglycan in
muscle cells of individuals with DMD. Interestingly,
we found that we could successfully target both UTRN A
and B promoters with single sgRNAs and a combination
of three sgRNAs; however, we found that upregulation by
guides targeting promoter B was more robust.
The different potentials of our A and B guides to activate
UTRN expression could be explained by the epigenomic
landscape surrounding the promoter regions (Figure 1D;
Figure S1). Although the relationship between genomic
features and gene expression is complex, shorter genes
generally correlate with higher transcript levels.45 For
this reason, we speculate that if both the A and B pro-
moters had similar promoter-proximal polymerase II ki-
netics, the B promoter, which is located more than 50 kb
downstream of the A promoter, could result in more-effi-
cient transcription of UTRN. Given that a small increase
in utrophin is sufficient to restore b-dystroglycan levels
and this phenomenon is true for other genetic dis-
eases,46,47 it will be important to further establish the
mechanisms behind the differential ability to upregulate
the transcription and translation of genes of interest.
Future experiments focusing on both promoters could
reveal new insights into determining the preferred target
promoter for developing CRISPR/Cas9-based therapeutic
strategies for DMD. Importantly, previous data have
shown that the efficiency of CRISPR/Cas9-mediated gene
upregulation is very gene specific.27 Thus, this approach
could serve as an alternative to current pharmacological
drug-development strategies, which modulate pathways
associated with disease pathogenesis. Furthermore, in vivo
targeting using AAVs with specific tissue tropism (e.g.,
AAV9 for striated muscles) will add to the specificity of
CRISPR-mediated upregulation because delivery can be
tailored to particular cell types of interest.
CRISPR-mediated targeted removal of a dominant allele
is distinct from the editing of homozygous and X-linked
recessive mutations because the designed guide RNA
would require allele specificity. This can be particularly
challenging given that the difference between two alleles
is often only one nucleotide, as in the case of the FGFR3
c.1138G>A mutation. Here, we have shown that one can
achieve allelic specificity by designing allele-specific and
PAM-discriminating sgRNAs. Allele-discriminating guides
based on a single SNP in the guide target itself have been
previously reported,48,49 but ours is an example of an
allele-specific PAM-discriminating guide. The pathogenic
FGFR3 c.1138G>A mutation is unique in that the 50 N of
the 50-NGG-30 PAM is the discriminating nucleotide be-
tween the two alleles. The striking preferential targeting
of the mutant allele indicates that the first position in the
PAM can dramatically affect sgRNA activity, an observation
previously reported by two different groups on the basis of
analysis of diverse sgRNA libraries.30,50 Moreover, Gagnon
et al.50 have suggested a preferential targeting of the
50-AGG-30 PAM over the 50-GGG-30 PAM, which is in
agreement with the data presented here. It should
be emphasized, however, that recent studies evaluating
activities of almost 2,000 sgRNAs in zebrafish in vivo
demonstrated preferential utilization of either the G or C
nucleotide in the variable position of the NGG PAM,51
further highlighting current limitations in bioinformatic
predictions of themost active sgRNAs. Therefore, a possible
use of an individual PAM-discriminating sgRNA should be
considered on a case-by-case basis in situations where
allele-specific guide RNAs cannot be designed or display
similar activities targeting both alleles. Nevertheless, weThe Amprovide evidence that PAM-discriminating sgRNAs can cor-
rect dominant-negative disease-associated sequence vari-
ants, and this might serve as an alternative approach for
allele-specific targeting of disease-causing mutations.
An increasing number of genetic disorders are caused by
chromosomal rearrangements and CNVs. However, treat-
ments targeting the underlying causes of these disorders
are currently not available. Although deletion of genomic,
single-copy DNA has been shown with the use of zinc fin-
gers52 and two guides in the CRISPR/Cas9 system,25,53
removal of duplications has not yet been demonstrated.
Furthermore, it has been unclear whether this type of ge-
netic correction would restore a fully functional gene.
Here, we developed a strategy that employs the CRISPR/
Cas9 system to remove duplicated regions within the
genome. Our strategy uses only one sgRNA, which creates
two DSBs because of the nature of a tandem (head-to-tail)
duplication (Figure 3B). Because we are targeting a
sequence within a duplication, the sgRNA target will be de-
tected twice, leading to the formation of two DSBs and
hence the removal of the intervening sequence, which
equates to the total size of the duplication. There are
several advantages to this strategy. First, the design of
RNA guides is not limited to specific sequences near the
breakpoints. This allows for the selection from a large
pool of guide RNAs targeting any portion of the duplicated
sequence, therefore greatly reducing possible off-target ef-
fects. Second, given the limited loading capacity of poten-
tial in vivo delivery vehicles such as AAV9, strategies using
the least amount of CRISPR components will be critical for
the development of further therapeutic applications. We
first used this strategy to successfully remove a large X
chromosome rearrangement containing MECP2, indi-
cating that this approach can target several chromo-
somal-duplication syndromes. Importantly, off-target
analysis showed no significant hits in the top 60 sites pre-
dicted by the CRISPR Design tool29 (Table S2) and top 12
hits predicted by COSMID32 (these hits were validated by
next-generation sequencing and the GeneArt Genomic
Cleavage Detection Kit [Figure S3]), suggesting that the ac-
curacy and safety of our system lend themselves to a viable
strategy for future therapeutic developments. It is impor-
tant to note that there were discrepancies between the
off-target sites identified by the CRISPR Design tool and
those identified by COSMID, further emphasizing that
there is a need for new non-biased off-target analyses,
such as GUIDE-seq54 and/or high-throughput, genome-
wide, translocation sequencing (HTGTS) methods.55,56
To determine whether our previously undescribed dupli-
cation-removal strategy has broader applicability, we
applied this approach to individuals affected by DMD. To
date, treatments that specifically target duplications in
DMD have not been extensively studied even though du-
plications of one or more exons compose approximately
10% of the DMDmutation spectrum.41 Recent therapeutic
strategies undertaken by other groups include gene-
replacement therapies, which deliver truncated buterican Journal of Human Genetics 98, 90–101, January 7, 2016 97
functional microdystrophin genes.57,58 Other strategies
utilize exon skipping, where antisense oligonucleotides
complementary to regions of premature DMD mRNA are
used to induce skipping of one59,60 or more61 exons and
hence restore the open reading frame to produce a shorter
dystrophin protein. Similarly, previous studies from other
laboratories have demonstrated that the CRISPR/Cas9 sys-
tem can be utilized to restore the reading frame of large de-
letions in DMD.25 However, one potential shortcoming of
these approaches is that the shorter dystrophin product
ameliorates the disease phenotype only to the extent of
making it similar to that of individuals affected by Becker
muscular dystrophy, where a truncated yet functional dys-
trophin protein is detected.62 Thus, our data are of partic-
ular importance given that removal of a duplication re-
stores the full-length dystrophin, which represents new
therapeutic opportunities for DMD-affected individuals
with duplications.
An important consideration in establishing a treatment
for DMD is determining how much dystrophin is neces-
sary for ameliorating the disease phenotype. It is esti-
mated that in humans, about 20% of truncated dystro-
phin is sufficient to cause a less severe phenotype and
maintain ambulation.63,64 Furthermore, studies in mdx
mice suggest that approximately 5% of full-length dystro-
phin can improve disease pathology and that >20% is
needed for fully protecting muscle fibers from exercise-
induced damage.65–67 One potential challenge for this
treatment strategy is the delivery vehicle for Cas9 and
sgRNAs. In this study, we used lentiviral vectors because
they easily infect primary cell cultures. However, future
in vivo studies will include more clinically feasible vehi-
cles such as AAVs. Nonetheless, although it is difficult
to extrapolate our in vitro data to potential in vivo situa-
tions, our data demonstrating 4.42% of full-length dys-
trophin accompanied by restoration of components of
the DGC are promising as we currently continue to
explore the in vivo therapeutic feasibility of this
approach.
Recent estimates suggest that about 400 million people
worldwide are affected by orphan diseases, and most of
them are caused by primary genetic abnormalities.68
Although orphan-drug development has made some
progress over the last few years, most genetic disorders
lack efficient treatments and are often associated with a
life-threatening or life-limiting disease trajectory. The
CRISPR/Cas9 system provides a rare opportunity to
employ a technology that can not only target the under-
lying primary disease-causing genetic abnormalities but
also alter genetic modifiers that play a critical role in
the pathogenesis of a certain disease. Here, we have devel-
oped a pipeline in which genome-engineering strategies
use easily accessible cells from affected individuals and
provide evidence of the versatility of the CRISPR/Cas9
system for various genetic conditions. As a mutation-in-
dependent approach, we demonstrated the feasibility of
modulating disease-modifying genes, such as UTRN in98 The American Journal of Human Genetics 98, 90–101, January 7, 2DMD. Furthermore, we found that targeted elimination
of disease-causing alleles can be employed as a therapeu-
tic strategy for disorders caused by dominant-negative
mutations. Finally, we demonstrated that individually
tailored single RNA guides are able to remove large dupli-
cated genomic rearrangements in two different genetic
disorders. As outlined here, proof-of-concept studies uti-
lizing affected individuals’ cells are critical in laying the
foundation for further research into the application of
these therapeutic strategies for safe and efficient post-
natal, in vivo treatments for numerous inherited
disorders.Supplemental Data
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